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ABSTRACT
The biotechnology industry has experienced fast growth during the first 30 years of its
existence but is now reaching a stage of maturity. Companies are being challenged by
weak pipelines and patent expirations, as well as increasing regulation. Mergers and
acquisitions are frequent, and companies are forced to reduce planned capital
expenditures, as well as restructure with personnel cuts and facility reductions. This
thesis focuses on the affect those changes are having on the development of capital
projects. It researches the environment as it used to be and what is now bringing the
changes. Through literature search and case study, the thesis aims to capture the reasons
for why the main driver of new facilities construction has shifted from time to cost and
the affect that is having on the management and delivery of such projects.
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1 PART I: Introduction and Background
1.1 Introduction
This thesis is developed from a six-month internship at Amgen, a leading human
therapeutics company in the biotechnology industry. The internship was focused on the
construction of a new facility in one of their manufacturing locations.
The focus of the internship was intended to be on the cost estimates for the construction
of the facility. However, during those six months, the company was faced with the same
challenges as other companies in the industry. The nature of new project development
was changing. The companies no longer had the capital to spend on new projects and had
to cut back in expenditure, resulting in layoffs, facilities reductions, and overall changes
to future project planning. The companies were forced to reassess the need for new
capital projects, and thoroughly examine current project expenditures.
The new facility project at Amgen was planned as a major expansion to this
manufacturing plant. It was intended to include formulation and fill, in a separate
building with its own utilities as well as administrative building. As the internship started,
the project had been going through the basis of design for over a year. The kick-off
meeting had been held and the team was ready to move to the detailed design when
Amgen announced that the need for the project had to be reassessed due to the challenges
the company was being faced with as a result of the changes in the biotechnology
industry. What initially was meant as a risk mitigation project with optimally designed
facility with potential expansion capability as fitting to the overall site master plan had
changed to simply building a facility that would be sufficient for the Food and Drug
Administration (FDA) compliance. The desired strategy was no longer to go ahead with
the optimal design, but to redesign to cut down cost as much as possible.
For the next six months the team worked on redesigning the facility. Several design
alternatives were considered, ranging from the original design of a state of the art facility,
to trying to fit the project scope into an already constructed shell at the plant. As the
design kept on changing, and the start date of construction was pushed back further, the
focus of the internship shifted towards looking at the main drivers in a new capital project
when the company is being faced with the urgency of having to construct a new facility,
but not having capital to go ahead with the optimal design. What different construction
management methods are desirable when a company in the biotechnology industry lacks
capital and time, but still has the need to go ahead with the construction project? What
gets sacrificed in terms of the cost, time, and quality of the project depending on the
choice of approach?
In order to answer this question there is initially a need to take a close look into the
biotechnology industry in the United States, to see where it is coming from and what is
driving the changes today. After an industry analysis, the thesis discusses the construction
of a new facility for a biotechnology company and follows up with a case study of the
new facility construction at Amgen.
1.2 Biotechnology industry
The biotechnology industry originated in the 1970s, based largely on a recombinant DNA
technique that was published by, Stanley Cohen of Stanford University and Herbert
Boyer of the University of California (BioWorld, 2007). The recombinant DNA
technique is a method of making proteins in cultured cells under controlled
manufacturing conditions. In the biotechnology industry this biochemical science is used
to produce on large scale products for human health, food supplies, and the environment.
1.2.1 Current market
Thirty years ago, the biotechnology companies were often founded by idealistic scientists
and run more on vision than corporate experience. By the end of 2005 there were 1,415
biotechnology companies in the United States, of which 329 were publicly held
(BioWorld, 2007). The industry has been growing fast, but despite there being enough of
statistical evidence that highlight the growth across the healthcare research pipeline the
industry is now showing signs of reaching maturity in its lifecycle. Evident are the
strengthening pipelines, revenue growth, and progress towards profitability. This success
comes with challenges that are born from the convergence in time of innovative new
products, newly profitable companies, and greater responsibility including escalating
regulatory challenges and heightened investor scrutiny (Ernst & Young, 2007).
Biotech
Stages
Indicators * New products introduced * Increasing sales: * Competitors * Continuous decline in
into market to establish a 20% increase in leaving market sales
clear identity 2006, compared to * M&A activity: * Unfavorable economic
* Promotions conducted to 14% in previous year major biotech conditions and lingering
maximize awareness * Emerging acquisitions in the effects of competition exist
customers past few years
* Repeat purchases * Sales velocity is
by customers reduced dramatically
* Sales volume
reaches steady state
Figure 1 State of growth of the biotechnology industry'
The biotechnology products treat a wide range of health issues. With the aging population
in the United States, the demand for the biotechnology medications remains strong. The
established products, along with innovative new drug launches, are predicted to continue
generating strong revenue for the companies. The pattern of strong growth can clearly be
seen by looking at the performance of the publicly traded companies, based on the data
from the financial statements (see example in Table 1). In the past few years, stock
performance has been supported by major biotech acquisitions. The acquisition activity is
generally high in the biotechnology industry due to the need to fill product pipeline gaps,
acquire manufacturing capabilities, or to scale existing business segments.
1Source: Adapted from a diagram used in a case prepared at the Keck Graduate Institute of Applied LifeSciences (Agrawal, Kelly, & Finegold, 2001)
According to Standard & Poor's, the leading companies in the biotechnology industry are
predicted to grow their market-weighted earnings per share (EPS) by about 20% from
2007 to 2009, based on solid revenue growth, increasing operating leverage, and the use
of share buybacks (Standard & Poor's, 2008).
Year
Sales
Revenues
R&D Expense
Net Loss
No. of Public Companies
No. of Companies
2005 2004 2003 2002 2001 2000
32.1 28.1 28.4 24.3 21.4 19.3
50.7 43.8 39.2 29.6 29.6 26.7
19.8 19.6 17.9 20.5 15.7 14.2
4.1 6.8 5.4 9.4 4.6 5.6
329 331 314 318 342 339
1,415 1,346 1,473 1,466 1,457 1,379
Amounts are in billion USD
Table 1 US biotechnology industry statistics from 2000 to 20052
For the past few years the biotechnology industry has seen major changes. Most
noticeable have been the increased regulatory constraints and challenges. This increased
scrutiny has lead to rising sales and marketing expenditures as the companies have tried
to replenish from the suffering of tarnished reputation.
The total market capitalization of the public biotechnology companies in 2007 was
$338B (Yahoo! Finance, 2007). Over 50% of the market share is held by the top three
biochemical companies, Amgen, Genentech, and Gilead Sciences. Although the industry
has seen changes, the companies still bear the values of the entrepreneurial founders, who
were driven by the desire to improve human lives rather than by aspirations of financial
gain.
2 Source: Ernst & Young (BioWorld, 2007)
1.2.2 Amgen Inc.
Amgen is a leading human therapeutics company in the biotechnology industry. It was
founded in 1980 and is headquartered in Southern California. The company engages in
the discovery, development, manufacture, and marketing of health care products, for
supportive cancer care, nephrology, inflammation, and oncology. It is a pioneer in the
development of novel products and launched the biotechnology industry's first
blockbuster medicine. Today, the principal products include Akranesp and EPOGEN that
stimulate the production of red blood cells to treat anemia; Neulasta and NEUPOGEN,
which selectively stimulate the production of neutrophils, a type of white blood cell that
helps the body fight infections; and ENBREL that blocks the biologic activity of tumor
necrosis factor by inhibiting TNF, a substance induced in response to inflammatory and
immunological responses, such as rheumatoid arthritis and psoriasis (Yahoo! Finance,
2008).
Amgen has six manufacturing locations in the United States and offices in more than 30
countries, with around twenty thousand employees. The company markets its products to
healthcare providers including physicians or their clinics, dialysis centers, hospitals, and
pharmacies primarily in the United States, Europe, and Canada.
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Figure 2 Amgen's operation worldwide3
33 Source: Amgen Inc.
In 2006, Amgen had plans to engage in the largest manufacturing capacity expansion in
the history of the biotechnology industry. The largest new capital projects were twofold.
A major production site was planned in County Cork, Ireland. Once operational, this site
would include capacity for process development, bulk protein production, formulation,
fill and finish, as well as quality testing. This plant was meant to play a crucial role in the
expansion of Amgen's global manufacturing network, producing medicines to serve a
growing number of patients in Europe and other parts of the world. Another major
expansion was planned for the plant in Juncos, Puerto Rico, by constructing a new
facility to manufacture EPOGEN and Akranesp. The company also planned to add a new
formulation, fill and finish facility and additional bulk protein manufacturing capacity to
the plant.
But the year of 2006 was difficult for Amgen despite strong growth of the biotechnology
industry. The company recorded a 14.8% increase in sales, to $14.27 billion. On the other
hand, net income was $2.95 billion, 19.7% less than in 2005, and earnings per share were
$2.48, 15.4% less than the previous year (Truelove, 2007). Between the first and third
quarters of 2007, sales of Akranesp, the company's top product, slumped by 30% as after
FDA changed the label in response to unconfirmed safety issues which restricted
prescribing freedom of doctors. The company saw its stock sink, fueled partly by some
analysts who questioned the company's growth potential. With revenues driving the
expenses, Amgen announced in August that year its plans to cut and restructure. The
restructuring included reducing headcount by 12% to 14% of total staff, or 2,200 to 2,600
employees. To improve cash flow, the company set to reduce planned capital
expenditures by about $1.9 billion during the 2007 to 2008 period. In addition, the
company planned to close certain production operations and rationalize other facilities.
With main focus on future growth, the company's focus shifted from expansion towards
building the framework around the highest priorities in research and development and
operations. Executives at Amgen believed that restructuring would be completed by 2008
and would yield pre-tax savings of between $1 billion and $1.3 billion in 2008.
Following Amgen's global review on their business plans, they decided to reschedule the
execution of its project to build a new manufacturing capacity in Ireland. No changes
were planned for the amount of additional capacity intended to be developed in Ireland,
the overall capital investment, and the number of staff it planned to employ, but the
timeline was to be extended to allow for a more efficient and sequenced project execution
(Amgen, 2007) . However, the plan was to continue pursuing the project in their plant in
Juncos, Puerto Rico.
1.2.3 Future outlook for the industry
The operating environment for the biotechnology industry is expected to continue facing
the same challenges as emerged in 2007. With the government and the public keeping a
close eye on the safety and cost of the products, the companies have already moved to a
strategy of cost containment with various restructuring activities, lower capital spending,
and focus on product development. The demand is expected to stay strong due to the
aging population in the United States, with pricing pressure being the largest offset to the
strong demand growth in driving revenue growth. However, FDA has become more
conservative, which could contribute to a slowing industry pipeline.
According to Fitch Ratings, with lower capital spending the cash flow generation is
predicted to remain stable and although shareholder-friendly activities will continue, it
will be at a lesser extent due to decreased leverage buyout pressure associated with a
tightening credit environment. Moreover, Fitch Ratings believes that acquisition activity
will continue but that debt will remain relatively stable (Business Wire, 2007).
Merger and acquisition activity is expected to be the key driver of performance for the
biotechnology industry, as companies seek to bolster slowing pipelines with products and
technologies. In addition, several companies have announced aggressive share repurchase
programs, leveraging their sizable operation cash flows (Standard & Poor's, 2008).
1.3 Summary
The companies in the biotechnology industry are moving from the glory days of fast
growth where they had sufficient capability to finance new capital projects. The
companies didn't use to question the expenditure needed to complete the projects as fast
as possible to meet the market demand. When building new facilities, the delivery of the
project was primarily focused on the time. As it was often vital for the companies to
move fast, they were willing to put up with high cost for the benefit of having the
capacity needed. As times have changed, the companies have had to reassess the way
they manage new capital projects. The companies need to choose to manage their projects
in the most cost efficient way while they're still under the pressure of moving fast due to
the business drivers.
The following chapters of the thesis will look into the construction of new facilities in the
biotechnology industry. They will assess the methods used to manage the construction, as
well as the costs and benefits of choosing between those methods. As a case study of
managing such a project in the new environment of the biotechnology industry, the thesis
discusses the project arrangement and challenges faced for a construction of a new
Amgen facility.
2 PART II: Pharmaceutical facilities
In the biotechnology industry, the companies incur high fixed cost to develop a drug,
such as research and development (R&D) and investments in production facilities, but
have relatively low marginal cost for manufacturing the drug. As the companies are likely
to earn more on each additional unit of drug sold than they pay for producing that unit, it
is most important to keep a low fixed cost. With limited resources, and as large-scale
manufacturing continues to intensify, it is important for the companies to effectively
strategize their new capital project development.
2.1 Project Life Cycle
To build and validate a new facility in accordance with the regulation guidance requires
long lead times and heavy fixed costs. According to industry estimates, a new large-scale
Active Pharmaceutical Ingredients (API) facility with a total bioreactor capacity of
roughly 100,000 liters can take three to five years to build, and can cost from $200 to
$400 million (Agrawal, Kelly, & Finegold, 2001). From the perspective of the owner, the
project life cycle for a constructed facility may be illustrated schematically in Figure 3.
Figure 3 Project life cycle of a constructed facility4
The stages of development do not have to be sequential. Some of them may require
iteration and others can be carried out in parallel or with overlapping time frames,
depending on nature, size and urgency of the project. It also depends on the in-house
4 Source: Schematically drawn project life cycle according to Project Management for Construction
(Hendrickson, 2003) adapted for the process of capital project flow for Amgen Inc.
capabilities of the owner where there is need to seek professional services for the work.
Due to the specialized nature of the biotechnology industry, the owners usually choose to
develop the in-house knowledge to be deeply involved in the development of the project,
and pick a team of designers and builders with whom they can develop good working
relations over the years.
2.1.1 Business Case
The initiation of the new construction projects depends on several market drivers and
resistors. Some examples include new product introduction, regulatory requirements,
existing product capacity shortfalls, and process improvements (Mongiardo & Bobrow,
2005). Due to the amount of planning needed, the capital intensity and construction time,
the most important factor in the business case is the long range demand forecasting.
For production capacity building strategies, companies in the biotechnology industry
have cycled between having too little capacity to having too much capacity and have
historically had extremely high capacity utilization rates. With large number of products
in the pipeline the companies drive to build capacity, but as products fail clinical trials
and with a downturn in the economy, the companies seek balance in their production
capacity. In 1998 ENBREL, a drug that blocks the biologic activity of tumor necrosis,
was first released for commercial use. After two years on the market it was so popular
that the producer5 was unable to manufacture enough to meet demand and had to
introduce a waiting list for prospective patients. This motivated both drug developers and
contract manufacturing organizations (CMO's) to invest in additional manufacturing
capacity. From 2003 to 2006 the capacity for mammalian cell culture production6
increased by almost 200% (Business Insights, 2007). Despite this substantial expansion
in manufacturing capacity there are concerns that the unequal distribution of it may lead
5 ENBREL was developed by researchers at the biotechnology company Immunex, which was
subsequently acquired by Amgen in 2002.
6 Biotechnology drug manufacturing is primarily of two types: microbial manufacturing (products made
from bacteria) and mammalian cell manufacturing (products made from complex mammalian cells).
to supply shortages, as majority of the capacity is being concentrated within fewer than
10 companies.
According to Business Insights the number of biotechnology products is expected to
increase by about 50% to the year of 2010, and a closer look at the current research and
development pipeline shows that the number of drugs in various stages of development,
as well as the increasing demand for biotechnology products, will continue to grow the
need for greater manufacturing capacity (Tulsi, 2006). For the capacity strategies it is
becoming important for the companies to decide whether to internalize the production or
outsource to CMO's. Regulatory constraints in the biotechnology industry, as well as the
immaturity of the technology, used to stand in the way of the companies exploring those
options. However, now that the CMO's have developed deeper understanding in the
process, the risk of outsourcing the manufacturing has been reduced, making it a viable
option for the companies to consider. What ultimately determines the decision is the cost
relative to benefits.
The main advantages of outsourcing are lower capital investments and the associated
reduction in investment risk. The biotechnology companies can thereby focus on the
research and development and marketing of their products. In addition, for companies
without manufacturing experience the outsourcing helps them avoid the steep learning
curve. The disadvantages associated with outsourcing to a CMO include the challenges
with finding a CMO that has the right fit of capacity and technology and relying on a 3"
party to be compliant to all regulatory bodies. The potential higher cost of the goods7 also
decreases the company's profit margin for the product (Beckman & Rosenfield, 2008). In
addition, the pricing pressures drive the companies to seek for low cost by offshoring to
countries that offer lower salaries, highly educated workers, and supportive governments.
However, the cost savings alone are not sufficient measurement for the optimal facilities
development strategy. Hidden costs and risks need to be carefully evaluated, such as
maintaining control over the process, the intellectual property, and quality.
7 In many industries, outsourcing is done to obtain lower costs, but in the biotechnology industry this is not
always the case.
The advantages of not outsourcing but rather building up the company's own
manufacturing capacity include the ability to design and build to optimize the process and
build up in-house expertise, which is valuable for the company's long term strategy and
improvements for future products. It enables the company to maintain lower cost of
goods and to have full control over quality and regulatory issues. The disadvantages
include the risk involved in timing the capacity expansion, since decision needs to be
made long before capacity needs are finalized. In addition, the capital investment is high
and the fast improvements in new technologies may create obsolete or idle capacity.
The manufacturing strategy needs to be in place early, typically prior to Phase III, in
order to make registration batches and produce market launch material from same
facility. However, there are many uncertainties with making an early decision, with
challenges in failures from clinical to approval, regulatory, and commercial. The timing
of capacity expansion is critical, or as stated in the report In Vivo in December 2001:
"You have to have the internal fortitude to invest in unique manufacturing sites. And if
you want to be in biologics big time, it's too late to start thinking about manufacturing
once your molecules are in development. It takes a little bit of foresight and sometimes
sticking your neck on the line" (Welch, 2003).
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Figure 4 Timeline for antibody project compared to timeline for new production facility8
8 Source: Abbott Bioresearch Center (Welch, 2003)
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Deloitte Consulting used the following figures to compare the net present value for the
two scenarios of building a facility for capacity expansion versus outsourcing to a CMO:
Expected time to build an average biologics plant
(biotech company self-manufactures)
Expected time to build an average biologics plant
(biotech company outsources)
Cost to build an average biologics plant
Average time to reach peak revenues
Useful life of a plant to calculate depreciation
Effective rate
Typical gross margin for a biologics company
Gross margin for a company outsourcing to a CMO
SG&A as a percentage of sales (company self-manufactures)
SG&A as a percentage of sales (company outsources)
R&D as a percentage of sales (company self-manufactures)
R&D as a percentage of sales (company outsources)
Initial investment made by the biotech company as a percentage
of the cost of the plant
Cost of capital
Operating margin
Post-tax cost of capital
Investment made to remodel the plant for the new drug as a
percentage of investment to build a new plant
Table 2 Key statistics for a new biotechnology manufacturing facility9
4 years
3 years
$400 million
5 years
40 years
35%
80%
65%
20%
18%
20%
18%
10%
15%
20%
6.4%
25%
9 Source: Assumptions as based on the economic valuation model used by Deloitte Consulting to
determine the cash flow for a new facility and outsourcing to CMO (Chao & Lakshmikanthan, 2006)
Based on the calculations, the initial investment required to build a facility to
manufacture in-house is much higher than outsourcing, which requires the biotechnology
company to have the ability to raise high capital. However, for a drug that has high
expected peak revenues the company should not outsource as it will not have to pay a
premium to the CMO to share the risk. For a drug with expected revenue below $200
million the company should not invest in its own manufacturing facility (Chao &
Lakshmikanthan, 2006).
2.1.2 Design
Various possibilities may be considered in the conceptual planning stage, and the
technological and economic feasibility of each alternative will be assessed and compared
in order to select the best possible project. The financing schemes for the proposed
alternatives must also be examined, and the project will be programmed with respect to
the timing for its completion and for available cash flows. As the definition of the project
objectives and scope has been determined the different types of estimates are required as
a project evolves (Barrie & Paulson, 1992):
- Conceptual Design: Used to determine whether the contemplated project scope is
feasible. Prepared early in the project, prior to engineering design completion.
Will incorporate new information from design to obtain an updated estimate of
the project.
- Basis ofDesign: Prepared from completed plans and specifications.
- Detailed Design: After the scope of the project is clearly defined, the detailed
design provides the blueprint for construction. The project cost is forecasted
within allowable limits from a combination of conceptual and detailed
information. The cost estimate serves as the baseline for cost control. This stage
often includes partial contract and other procurement awards.
2.1.3 Construction
As soon as Basis of Design is complete, the construction and procurement phase can
begin, depending on the availability of design. This stage needs to be carefully planned
and controlled for the delivery of materials and the erection of the project. After the
construction is completed, there is usually a brief period of shakedowns of the
constructed facility before the commissioning and qualification process.
2.1.4 Commissioning and Qualification
The biotechnology industry in the United States is regulated by the Food and Drug
Administration (FDA), the Environmental Protection Agency (EPA), and the Department
of Agriculture (USDA). The FDA regulates the development, manufacturing and
marketing. The term used for the enforced control by FDA of the manufacturing and
quality control testing is Good Manufacturing Practice (GMP) 10 . GMP is designed to help
assure the quality of drug products by ensuring several key attributes, including
correctness and legibility of recorded manufacturing and control documentation. By
legislation, the manufacturing facilities are subject to FDA approval and periodic
inspection. The GMP regulations affect the architectural and building engineering
components of the facility along with equipment and systems. The FDA issued the
document International Conference on Harmonization (ICH) of Technical Requirements
for Registration of Pharmaceuticals for Human Use guide Q7A, which is intended to
provide guidance regarding GMP for the manufacturing of active pharmaceutical
ingredients under an appropriate system for managing quality (FDA, 2001).
The GMP's standards are integrated into every activity of construction projects and its
conformance is partly determined through the review of documentation done. Some GMP
requirements are specific and dictate the use of technology in the facility, while others
give room for interpretation. Compliance risks need to be appropriately and proactively
managed as incorrect documentation can result in FDA observations of nonconformance,
which can delay FDA approvals.
10 For the purposes of the thesis, the terms current good manufacturing practices (cGMP) and good
manufacturing practices (GMP) are equivalent.
2.2 Construction Engineering Management
When it comes to organizing the project management throughout a project's life cycle,
there is no single best approach. Among the construction engineering management roles
are the project management planning, cost management, time management, quality
management, contract administration, and safety management. The owner chooses an
approach based on the project and their knowledge in construction engineering
management. Each approach has its advantages and disadvantages, and needs to be
chosen based on what is beneficial for the particular project, its type, size, and location.
As the biotechnology industry has changed the companies have been faced with the
challenge of increasing their focus on cost management. As the new capital projects
require high fixed cost, reducing it is often challenging unless novel approaches for the
facility strategy are introduced or capital expenditure is deferred, by slowing the project's
progress and thereby lengthening the project timeline. However, new capital projects are
often under the pressure from the company's overall strategy to shorten the project
timeline since earlier decisions impose higher risk on the project to change. Thereby, it
becomes a challenge to successfully manage simultaneously both time and cost.
2.2.1 Time Management
The timing of initiating a facility project is influenced by the market pressure. Proposed
capacity expansion can fall through, due to deferred FDA approval or other impacts on
the forecast of expected sales. The owners however, often need to take chances since high
R&D investments can be at stake if the production capacity is not available when needed.
Various affects, such as failure to be the first mover on the market, and patent expirations
can influence the decision. As in other technology intensive industry the trend in the
biotechnology industry has been to push for shorter life cycles. Capital availability has
enabled the companies to make high investments and sacrifice some cost associated with
striving for fast construction in order to keep up with the market drivers.
When pushing for shorter project life cycle, the owners often forego thorough planning
and feasibility study and proceed to construction with inadequate definition of the project
scope. Inevitably, redefining the project scope is more expensive after the construction
work has started. However, the companies have had to evaluate that risk in comparison
with the risk of loss of profit resulting in not getting the product out on the market in
time.
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Figure 5 Simplified Gantt chart for the manufacturing facility timeline"
The front end planning of the schedule is information intensive, but is highly important
and it has been shown that projects that have invested more time and resources in front
end planning have proven to be more successful.
2.2.2 Cost Management
When organizing the project the owners need to plan the cost throughout the life cycle of
the constructed facility rather than only looking at the initial construction cost. Decisions
made at the beginning of the project life cycle have far greater influence than those made
at later stages (see Figure 6). The design and construction decisions will influence the
continuing operation cost and the revenues over the facility lifetime. Small savings
during construction may not be worthwhile if the result is much larger operating costs or
not meeting the functional requirements for the new facility satisfactorily.
" Source: Diagram used in a case prepared at the Keck Graduate Institute of Applied Life Sciences, basedon sources from U.S. Bancorp Piper Jaffray, Biogen, and IDEC Pharmaceuticals (Agrawal, Kelly, &Finegold, 2001).
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Figure 6 Ability to influence construction cost over timel2
Depending on the in-house capability of engineering and construction management of the
owner, there may be a need to seek the expertise of outside professionals to provide
adequate planning and feasibility studies. Moreover, by involving the operating
management from the beginning of planning stages the owners can ensure that the quality
of the constructed facility takes into consideration the cost involved in operation and
maintenance.
Owners that have engineering and construction divisions will often treat them as
reimbursable, independent organizations. Comparing the cost involved with outside
consultants can therefore be misleading, as false economies in reimbursable costs can
indeed be very costly to the overall organization. For the owners that do not have the in-
house engineering and construction management capability it is important to establish an
ongoing relationship with outside consultants in order to respond quickly to requests.
12 Source: Adapted from a diagram used in a case prepared at the Keck Graduate Institute of Applied Life
Sciences, based on sources from U.S. Bancorp Piper Jaffray, Biogen, and IDEC Pharmaceuticals (Agrawal,
Kelly, & Finegold, 2001).
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Figure 7 Cost breakdown of new facility' 3
Construction projects often involve high uncertainties and construction cost can go way
over the estimate based on inadequate scope definition. However, the constructed facility
is a success for the owner if it can derive reasonable profits from the operation. It is not
given that profit will be higher if construction cost is kept lower, since that can mean
having to increase the project duration on the expense of bringing the product to the
market at the time needed.
2.3 Contract Administration
After generating enough information for the initial planning of the basis case, the owner
needs to decide on the appropriate project delivery method, pricing, and allocation of the
project risk to the parties involved in the design and construction phase.
2.3.1 Project Delivery Methods
Facilities construction in the biotechnology industry involves a high degree of
technological complexity. The owners are usually deeply involved in the development of
13 Source: Diagram used in a case prepared at the Keck Graduate Institute of Applied Life Sciences, based
on sources from U.S. Bancorp Piper Jaffray, Biogen, and IDEC Pharmaceuticals (Agrawal, Kelly, &
Finegold, 2001).
the project, and pick a team of designers and builders with whom they have developed
good working relations over the years. The owner can chose to either select separate
organizations for design and construction, or to select a single organization or a joint
venture to handle both functions.
Contract Type
Separation of organizations
Integration of organizations
Impact on shorter Impact on lower
project completion time overall project cost
Low High
High Medium
Table 3 Appropriateness of different contract types for different projects
The main factors that the owner uses to decide the appropriate project delivery method
are the size and complexity of the project, the pressure on cost and schedule, and the
owner's construction management capability.
Separation of organizations
When organizations are separated, one team handles the detailed design, and the project
is then awarded to a separate team that handles construction. In addition, for large
projects the owner may choose to get professional construction management. The most
noticeable effect on the overall project cost and the time schedule for the project using
this type of contract are the following:
- Schedule: Design and construction are done consecutively. Due to lack of
parallel activities this type of contract can have unnecessary lag between activities
that increases the overall time of the project.
- Cost: Since detailed design is completed upon the start of construction, there is
less need for rework and redesign that can lower the overall cost.
This type of organizing is the most common one, due to the fairness of competitive
bidding, but is less desirable when the project is large and complex and when the
company requires shorter project time due to market pressure.
The separation of the design and construction team can be undesirable as it leads to
isolation of the two teams within the project, where each team looks out for its own
interests. Some contracts even have a disclaimer of the responsibilities of the design team
related to the details of construction or for on-site inspection. This may possibly lead to
the contention of constructability of the design.
Integration of organizations
For large scale projects it has becoming increasingly popular to have one team doing the
design and construction 14. This team needs to have sufficient capability to take the project
through detailed designed to a constructed GMP compliant facility. There are different
ways to organize this, ranging from the owner doing all the project work, to contracting it
all to one firm.
- Owner-builder operation: In this type of contract the owner retains full control
over design and construction. The owner may choose to handle all work in house
or to subcontract part or all of the design and construction process, while still
retaining centralized decision making to integrate all efforts in project
implementation.
- Turnkey operation: In a turnkey contract, all the project work is contracted to a
contractor which is responsible for delivering the completed facility based on
preliminary design set forth by the owner. This can also include having to operate
the facility for a specified period 5 .
14 This type of contract is often referred to as Design Build or Design/Construct Contract.
15 This form of contract is called Build Operate Transfer.
This type of contract is desirable for the following effect on the project schedule and cost:
- Schedule: With shorter lead time due to faster hand-off of tasks between the
design group and the construction group, this method tends to be efficient in terms
of shortening the total time for the completion of the project. Since the contractor
is established early on, some construction pre-work activities can proceed
concurrently with the design which can result in considerably shorter schedule.
This can be done by organizing the construction activities in phases so that each
phase can be designed and constructed in a staggered manner.
- Cost: This type of contract also removes the friction that can be between the
design group and the construction group as in this contract they all work as a team
where the design is developed with constructability in mind. This leads to less
overall cost, as the team works together to find ways to reduce construction cost
with less need for design rework.
However, for this type of contract the owner needs to make sure that quality standards are
enforced as the team may be tempted to sacrifice quality to lower the overall project cots
or shorten the project time.
2.3.2 Construction Contracts
Public biotechnology companies are required to select contractors based on competitive
bidding. The rules for the bidding are carefully delineated to place all qualified
contractors on an equal footing for competition. Those rules are strictly enforced to
prevent collusion among contractors and unethical or illegal actions by public officials.
The detailed plans and specifications are usually prepared by the architectural and
engineering firm, which oversees the bidding process on behalf of the owner. The final
bids are submitted according to the owner's specifications. The owner uses the different
types of contracts to set forth the terms regarding allocation of risk of the project to the
various parties involved.
Contract Type
Lump Sum Contract
Unit Price Contract
Cost Plus Fixed Percentage Contract
Cost Plus Fixed Fee Contract
Cost Plus Variable Percentage Contract
Target Estimate Contract
Guaranteed Maximum Price Contract
Schedule overrun Cost overrun risk
risk assumed by assumed by
Contractor Contractor
Owner Owner
Owner Owner
Contractor Owner
Owner/Contractor Owner/Contractor
Owner/Contractor Owner/Contractor
Contractor Contractor
Table 4 Risk allocation for schedule and cost overrun for different contract types
Lump Sum Contract
The lump sum contract 16 is a onetime payment of money, as opposed to series of
payments. The contractor places in the bid the total amount to complete the facility
according to the detailed plans and specifications. In case there turn out to be cost
savings, they are typically retained by the contractor. Conversely, the risk of cost being
higher than estimated is also born by the contractor, and the underestimated cost reduces
the contractor's profit by that amount. This risk is embedded in the contractor's bid, by
placing a higher markup in order to take care of unforeseen contingencies. Contractors
however tend to place an accurately estimated markup due to that risk, as overestimating
the project may reduce the chances of the contractor to be the lowest bidder for the
project. A lump sum contract requires all the design documents to be completed and the
entire project construction to be awarded to one general contractor. With this approach
the final project cost is known at the start of the construction. However, it does not
incentivize the contractor to finish the project earlier and can therefore take the most
overall schedule time.
16 Lump Sum contract is also known as Stipulated Price or Fixed Price contract
Unit Price Contract
For a unit price contract the contract agreement is based on a list of unit prices submitted
by the contractor. The payments to the contractor depend on the actual quantities
multiplied by the quoted unit prices. This type of contract is common when the quantity
of materials or the amount of labor involved in some key tasks is uncertain.
For this type of contract, the owner bears the risk of inaccurately estimating the quantities
needed. The contractor however, can price according to own estimates on the quantities.
If there is a large discrepancy from the owner's estimates, the contractor may bid higher
unit prices for underestimated tasks and lower unit prices for the overestimated tasks for
increased profit.
Cost Plus Contract
In a cost plus contract the contractor receives compensation for the work done, plus some
bonus as stated in the contract agreement. For this type of contract there is no incentive
for the contractor to minimize the project cost since full compensation is given for actual
work done, plus the profit. Risk of cost overruns is therefore fully carried by the owner.
The bonus can be any of the following:
- Fixed percentage: The bonus can be in the form of a fixed percentage
proportional to the contractor's expenses. This contract leaves little incentive for
the contractor to keep down the project cost or to complete the project on time,
since every additional unit of actual work is paid for and increases the
proportional percentage bonus. This is therefore not a desirable contract method
for the owner but is sometimes used when there is a complete uncertainty about
the new facility, such as involving new technology or extremely pressing needs.
- Fixed fee: For this type of contract the bonus is in the form of a fixed amount,
independent of the contractor's expenses. This method therefore leaves some
incentive for the contractor to finish the job quickly as the profit is fixed, but the
risk of cost overrun is still born by the owner as the contractor gets fully
compensated for the actual job cost.
-Variable percentage: As a way to incentivize the contractor to stay on schedule
and to keep the cost down, the owner can have the contractor pay penalty if the
actual cost exceeds the estimated job cost, or reward the contractor if the actual
cost is below the estimated job cost. The risk of the cost overruns is still assumed
by the owner but the contractor has the incentive to keep it as low as possible.
Target Estimate Contract
In a target estimate contract, the contractor has the incentive to keep the cost low and to
stay on schedule by penalty or reward. The percentage of savings or overrun is usually
shared by the owner or contractor as specified in the contract. The contract also states the
rewards or penalties for different completion dates
Guaranteed Maximum Price
In the guaranteed maximum price contract1 7 the contractor gets compensated for the
actual cost incurred plus a fixed fee subject to a ceiling price. Unless the contract is
amended with a formal change order, the contractor bears the risk of cost overruns
beyond the estimate according to the contract documents. A change order is only made
when the owner amends the project scope, not because of price overruns, errors, or
omissions. If the cost is underestimated, the savings are either returned to the owner or
shared as specified in the contract. For a well defined project, the owner may also have
the contractor take the risk of actual project time.
17 Guaranteed Maximum Price contract is also known as GMP, Not-to-Exceed Price, NTE, or NTX contract
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3 PART III: New Amgen facility
Amgen's subsidiary in Juncos, Puerto Rico, called Amgen Manufacturing Limited
(AML), was founded with Amgen's acquisition of the plant in 1992, and started
operation in 1993. In 2002 Amgen announced the company's plans to expand the plant
and with FDA's approval on the first bulk protein manufacturing facility in 200518, the
plant has now been developed as a state-of-the-art facility.
3.1 New Capital Investments
With Amgen's strong corporate growth the plan for the plant in Juncos was initially set
up as for one-time expansion. With such a big capital investment it was highly important
to have large engineering resources and establish a large subcontracting network
(McCurry, 2006). As with all of Amgen's global engineering and construction projects,
the plant expansion was supported by Amgen's Corporate Engineering and Capital
Projects (CECP) group, which provided technical support and consultancy.
3.1.1 Project Location
Puerto Rico is an attractive location for this plant for several reasons. Puerto Rico is a
U.S. Commonwealth and operates under the security of United States laws for customs
protection, federal currency and banking, and intellectual property, yet companies do not
pay federal taxes until they repatriate profits. This creates an attractive business
environment for the biotechnology companies, since their operation in Puerto Rico is
taxed locally at a rate of 2-7%, depending on their investment in facilities and the number
of jobs created. The initial tax rate is locked in for 10-20 years, and is renegotiated when
it expires (Potera, 2007). In addition the companies get 25% credit on purchase of goods
manufactured in Puerto Rico, are incentivized for research and development work with
trust funds, soft loans, and a 200% special credit for expenditures involved in product or
process development. The country's location, the language 19, and access to skilled
18 FDA approved the manufacturing facility for bulk production of Neulasta and NEUPOGEN.
19 Spanish is the official language of Puerto Rico but the schools have mandatory English classes.
workers are among other important factors in the attractiveness of this location. Due to
the high number of biotechnology companies in the Puerto Rico, there is now a good
network of international and local companies that are engaged in the plant design,
engineering, validation services, packaging, instrumentation, environmental protection
and other essential services for the biotechnology companies (Potera, 2007).
The key factors in Amgen's decision to expand the operation at their plant in Juncos,
Puerto Rico have been this favorable business environment as well as the country's
commitment to developing biotechnology manufacturing capability. Throughout the
years of operation there, Amgen has built a solid foundation for the plant, and established
good relationship with the government in Puerto Rico, the community, and academia.
3.1.2 Plant Expansion Plan
Following the acquisition of the plant in Juncos, Amgen created a long term master plan
for the future expansion of the plant. The master plan was based on partial engineering
design and included the strategies for cost effective procurement of equipment and
material. As part of that strategy, Amgen identified the engineering design and
construction companies they had established good working relationship with, and with
whom they planned to work to leverage purchases.
The CECP group had the roles to oversee and review the engineering consultant
procurement efforts, as well as subcontracts. The plan was strongly focused on cost
efficiency, with oversight roles including monitoring overall procurement effort for
effectiveness and cost savings, suggesting various program costs saving plans, as well as
ensuring that cost efficient subcontracts were being issued by the contractor.
The plant expanded fast from the one building that was operational in 1993 to a state-of-
the-art biotechnology facility for bulk manufacturing in 2007, with 16 buildings, totaling
1.2 million square feet, and a fermentation capacity of 225,000 liters. Work force grew
from 450 full-time workers in 2002 to about 2,500 before lay-offs began in 2007 (Potera,
2007).
The facility has achieved an outstanding quality and compliance record. The expanded
facility includes manufacturing plants, full-testing quality and analytical labs, additional
syringe fill and freeze-drying capability and warehouses. It also includes process
development facilities, administrative and training buildings, a cafeteria, and a child care
center.
3.1.3 Previous Project Planning
The fast expansion of the plant required scheduling and cost estimates that allowed for
enough flexibility to enable fast track schedule to keep up with the demand. With the
schedule as the main driver, a typical project would be set up as cost plus contract, with
risk of schedule overrun assumed by the contractor but risk of cost overrun assumed by
Amgen. In order to reduce the overall time schedule, the project phases would overlap as
possible, mainly with less detailed design available before start of construction. This
required more bid packages and led to higher administrative cost. Risk of changes due to
inadequate design was higher which increased the overall project cost. However, due to
the nature of the industry at that time, it was considered a priority to minimize the risk of
loss of profit resulting in not having full capacity at the facility.
3.2 New Formulation and Fill Facility
The formulation and fill facility is highly important to the Amgen's operation in Juncos.
It is currently in the oldest building at the plant, a building that is over 25 years old and is
a legacy structure from the acquisition in 1992. The facility is therefore not built
specifically for this operation, and does not fulfill highest standards. This has raised
concerns of potential damage to the building, due to external environmental factors such
as mold and hurricanes. Analysis of the building indicated a high probability that the
plant could experience a significant shutdown. Shutdown of the facility would mean
inability to supply major clients and the loss of market share for major products.
About two years ago, Amgen decided to build a new formulation and fill facility to
operate in addition to the current facility and thereby mitigating the risk of financial loss
in case of a shutdown. As FDA got involved, that soon turned into a project that was
needed for FDA compliance. Throughout these two years, several design alternatives
have been evaluated for this new facility and the scope has been altered considerably.
Initially, Amgen had plans to build a state-of-the-art facility, but due to the challenges the
company was facing in terms of reducing new capital project expenditure, the team was
repeatedly asked to reevaluate the design to achieve maximum cost savings to meet the
project needs for FDA compliance. With the drivers of the project shifted so heavily to
cost the team was challenged to come up with novel ways to cut cost while still achieving
the desired licensure date. Those included considering erecting a modular building or
even using an already constructed shell at the plant. With almost two years of design for
this project, it was also foreseen that cost could be considerably less due to less
uncertainty and less administrative cost. This will also control the project delivery
methods used, as fewer bid packages will be needed, typical package will be lump sum,
and emphasis will shift to quality management.
3.2.1 Project Organization
Amgen operates this project with an owner-builder type of contract and utilizes single
sourcing of key construction and equipment vendors. Architectural engineering and
construction management is handled by both the contractor and engineering designer.
Other master services agreements are for validation and commissioning. The
responsibilities for architectural engineering are consultancy or specialty services as well
as equipment procurement. Construction management roles include issuing subcontracts,
purchasing long lead material, and purchasing equipment and instrumentation.
3.2.2 Project Scope and Design Alternatives
The project scope has changed considerably since it started almost two years ago. Over
twenty change orders have been approved, the number of vial and syringe lines has been
decreased, and requirements for operation efficiency have been altered.
During the six months internship a few different design alternatives were considered. The
alternatives went through feasibility studies and were presented to Amgen's senior
management with estimation on cost and time schedule. The following table lists some of
the alternatives considered.
Description
Location
Number of
Stories
Spine
Connection
Area (Gross
Square Feet)
Future
Expandability
Risk Adjusted
IRR
New stand-
alone building
south
Temporary
parking space
south of
facility
One-story
No
275,000 GSF
Yes
10.9%
New-stand
alone building
north
Finalized
parking space
north of
facility
Two-story
No
264,000 GSF
Yes
10.9%
New stand-
alone building
north w/spine
Finalized
parking space
north of
facility
Two-story
Yes
240,000 GSF
Yes
10.9%
Expand
existing
building
Already
constructed
shell as
building
expansion
Two-story
Yes
158,000 GSF
No
9.6%
Table 5 Different design alternatives for the new formulation and fill facility
Some design alternatives were similar enough to allow for minor adjustment in design,
for example when a new stand-alone building was presented at a new location. However,
as for other projects, with a considerable change in the scope there is a need for changes
in the definition of the process, Process Flow Diagrams (PFDs) and Piping and
Instrumentation Diagrams (P&IDs), equipment specifications and requirements,
preliminary facility fit, permitting requirements, and any regulatory requirements
(Mongiardo & Bobrow, 2005).
When evaluating those different alternatives the main focus was on cost. However, when
making recommendations the prioritized factors included evaluating the benefits that
came with having the spine20 connected to the building, ability to implement operational
efficiency, future expandability at that location, inspection capability within the building,
financial risk analysis, constructability, and the fit within the long term site master plan.
The design alternative for a stand-alone building went through the basis of design phase
from May 2007 to October 2007. The design team continued working on it although
other options were being considered at the same time. However, requests for changes
continued throughout the design phase, the design team was decreased, and work was
slowed down as much as possible. The actual completion of the basis of design for this
stand-alone building ended up being three times longer than originally planned.
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Figure 8 Planned and actual completion of Basis of Design from May to October 200721
As I left the internship, all design options we had been working on had been rejected by
the Amgen senior management and a new alternative was being considered. The plant
20 The spine is a closed hallway that connects the main buildings. It has both convenience and economical
value as employees use it to travel between buildings, or to transfer material and equipment.
21 Source: Diagram used in monthly report developed by Jacobs Engineering for November 2007 (JacobsEngineering, 2007).
had recently acquired more land with the purchase of a nearby plant which opened up for
new options. The idea was to build a new building right next to the building that currently
houses the formulation and fill operation, but that building had previously been on the
edge of the plant's site. This would allow for the approach to leverage the maximum
functionality of the formulation and fill facility, by operating in both buildings and
thereby reducing the square footage needed for the new building. Some modifications
needed to be done to the existing building, but by utilizing it the need for a CUP building
could be eliminated and the sources in the existing building could provide all utility
requirements. Basis of Design for this building was scheduled to begin in March 2008.
3.2.3 Project Drivers and Constraints
Building a new formulation and fill facility at the plant has a few constraints. Constraints
such as flooding and insurance restriction are needed, as well as location specific
restriction such as the following:
- Building classification: Depending on the classification of the building there is a
constraint on the hours of fire separation between buildings. Administration
building has classification B, manufacturing building F-l, and Warehouse S-1.
- Permitted building height: The allowable height of the building depends on the
building classification. A building that is fire rated 1 hour can be approximately
80 ft high, and a building rated 2 hours can be 160 ft high.
- Building mass limitation: Due to the mass limitation at the plant, there is a need
to allow a minimum of 120 ft to other Amgen buildings. Building separation
within development needs to allow 80 ft between buildings.
- Local Amgen Juncos planning rules: Local rules, Land Use Consultation
Document (Junta de Planificacion), set allowable areas for the whole site,
including parking etc. This is covered by overall site master plan.
The key project drivers for the new formulation and fill facility are any project element
that will have direct impact on the facility operations, construction cost, approval time
line, and compliance. Depending on the design and location, some of the key drivers are
the following:
- Hurricane standards: The building will need to be designed to resist Category 422
hurricane. After exposure to the hurricane, the building will require minimal
repairs and the production and utilities facility will need to be ready to be placed
back into a production mode within 7-14 days of the event.
- Power and water outage: The on plant diesel fuel storage can allow for a 3-4 days
of manufacturing operation in case of a power outage. The portable water storage
allows for 2 days of operation in case of water outage.
- Capacity: All plant utilities will follow the N+1 generating philosophy concept.
The N+ 1 generating philosophy is a risk mitigation approach where multiple
components (N) will have at least one independent backup component to ensure a
24/7 generating capacity operation in the event of a system failure. To be at a
level of N+1, the overall system integrity should not be impacted by the failure of
any one component, and should continue to function at acceptable performance
levels after the loss of any component.
- Plant floor design: All areas of the facility will be designed such that they are
accessible for monitoring of any detrimental conditions to the sterile environment,
and so that maintenance can be performed without interruption to manufacturing.
Where practical, the facility will be designed to have uni-directional product flow
so there will be no cross-over of dirty and clean equipment.
- Fill and finish equipment: The filling line will utilize either Isolation or RABS
technology. This technology is becoming industry standard. It has not been used
22 The hurricane is of Category 4 when wind reaches 131-155 mph. When wind exceeds 155 mph it is of
Category 5. Only one hurricane of Category 5 has hit Puerto Rico since 1852.
at the plant before but FDA is expecting it to be this time. Selection of all
equipment will be based on industry proven technology.
3.2.4 Time Scheduling
Design and construction of the new formulation and fill facility was intended to be based
on a fast track schedule approach with overlapping project phases. However, nothing was
to be bid without being 100% designed.
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3.2.5 Cost Estimates
As the project design changes, the cost estimates are updated based on the Basis of
Design documents. Cost estimates for each discipline, subcontract, construction
management staffing, general conditions, and overhead cost are reviewed monthly, but
23 Source: Diagram used in monthly report developed by Jacobs Engineering in March 2008.
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equipment cost estimates are reviewed bi-weekly (Amgen, 2007). The cost estimating
process uses change management logs (both approved and pending deviations) to help
forecast cost so that all known changes are included in the cost forecast.
When presenting a new design alternative to the senior management, it was considered
sufficient to update the cost estimate to a +/-30% accuracy. Although the Basis of Design
documents allowed for a +/-10% estimate, such an accuracy was not required until
needed for funding submittals (Jacobs Engineering, 2007).
3.2.6 Time and Cost Savings
This project is faced with the challenge to lower cost and defer capital expenditure while
still meeting the expected license date and the scope needed. Throughout every design
alternative the different cost benefits are evaluated, constructional, operational, the
plant's overall site master plan, and the fit to the corporate strategy.
After concerns over cash flow, the whole project was re-planned. The main difference
from previous projects was to allow the Basis of Design to be completed as a more
formal, standard package, start Detailed Design after completion of the Basis of Design,
and start construction after completion of Detailed Design. Equipment procurement was
only to proceed as required to support Detailed Design. Cash flow concerns also required
the engineering team to limit staffing for the start of the Detailed Design phase. This
reduction resulted in a further schedule extension of Detailed Design. Deferring capital
expenditure and re-planning the schedule in this way delays the FDA approval.
In order to minimize that delay, changes will be made to the required construction time
with innovative approaches such as using modular approach for the facility. This
approach has both cost saving benefits and compresses the schedule with shorter design
and implementation time, and an efficient approval process. With this prefabricated
approach the modular units are shipped ready to build on site. The capital cost savings are
mainly due to reduced engineering and construction manpower cost, and with most cost
factors pre-defined the risk of cost changes are low. With pre-engineered design the total
design time is estimated to reduce by at least 50%. The construction can happen
regardless of on-site progress or conditions and requires less on site manpower.
Conventionally field construction work is around 8 to 10 months but for this modular
approach the field construction work can be reduced to 4 to 8 weeks. It will also be cost
saving that Amgen has a strong purchasing power from the vendor. With 85% of the
work performed at the vendor's factory the overall capital cost savings are estimated to
be approximately 50% (Amgen, 2007).
With Value Engineering the project team has been able to come up with a list of things
that if feasible could potentially lower the total project cost. Due to the slow spend
approach between design and construction there was a significant float particularly for
the interior fit-out packages that could be reduced to shorten the schedule.
3.3 Three Lenses Analysis
This project is challenging in many ways. Not only due to the requirements to achieve the
project goal despite lack of capital, time, and senior corporate management support, but
also due to the other less defined challenges that the project team is faced with. Changes
in the corporate culture call for changes in behavior and even employee attire. The team
is intimidated by the worries of losing their job, but also of losing a friend when a
coworker is fired. As the company stock price falls, those employees with options worry
about the value of their shares in the future. Employees struggle to emphasize the validity
of their position for the team in order to prove that they are indispensable for the
company in order to keep their job. This leads to challenges in all areas, strategically,
culturally, and politically.
3.3.1 Strategic Design Lens
The mission of Amgen Inc. is to serve patients, and that mission is clearly understood by
the employees who many work for Amgen Inc. for the personal satisfaction it gives them
to know that they are serving patients. The company's values reflect the same mission
(Amgen, 2008):
- Be science-based
- Compete intensely and win
- Work in teams
- Create value for patients, staff and stockholders
- Trust and respect each other
- Ensure quality
- Collaborate, communicate and be accountable
- Be ethical
The project organization chart has around seventy team members but it is divided into
thirteen sections, where each section has as few as one team member. In this matrix
organization the team members are from different functional departments but report to a
single line, while the project manager coordinates the activities of the team members.
This form of strategic grouping may have been a good way when all team members were
fully utilized but as the work has slowed down it causes confusion and lack of oversight.
In addition, lack of communication has occasionally caused a conflict where a few people
want to do the same analysis, since the analysis concerns the role of their unit. The
project manager has the responsibility and authority to resolve various conflicts such that
the established project policy and quality standards will not be jeopardized.
Another challenge that the team faces is that most of the time not all team members are
located at the same place. There are a few linking mechanisms used to bridge that. An
online extranet has been set up to store all documents related to the project, which
connects the team members regardless of their location. Formal linking is in the form of
regular status meetings that are held to make sure all team members are on the same page
which helps facilitate the flow of information. To encourage informal linking the team
usually eats lunch together in the meeting room.
When it comes to making decisions on changes in design it is most challenging to align
the different groups and their goals. All groups realize though that they need to present
this project in such a way that the senior corporate management prefers. Cost and square
footage needs to be minimized, and that can mean having to sacrifice some other
preferences. When presenting a project recommendation the team meets first to discuss it
and make sure that everyone is on board. Then, once the phone conference call starts, it is
usually the project manager that does the talking to the senior corporate management at
Amgen's headquarters in Thousand Oaks, unless a specialist is needed to cover a certain
topic. In that way, whatever the project manager has to present comes as no surprise to
the other team members who sit patiently and await the senior corporate management's
verdict.
3.3.2 Cultural Lens
This project is highly important to the operation at the plant and to Amgen as a whole,
but at the same time it comes at a difficult time when the company has the strategy not to
be spending any money on such capital projects. It has therefore the symbolic meaning of
having reluctant support from senior corporate management.
Just like other companies in the biotechnology industry, Amgen has changed
considerably since it was founded. Changes are evident in the corporate culture and
employees that have worked for the company for a long time have witness it change from
leaders who were mainly science-driven specialists to business people that were drawn in
from other industries. The visible changes are for example in the appearance of the
employees, who used to show up to work in casual clothes but now wear more formal
attire. This is challenging as the company tries to translate the science and mission.
Most of the Amgen employees that work on this project are expats24. Moreover, majority
of those that work full time on this project are based in Conshohocken, PA, where the
office of the design engineering contractor is located. When looking at the team through
the cultural lens it is clear that it has not managed to create a strong coherent culture.
When in Conshohocken the team adapts to the culture of the contractor, and then returns
to the culture of Amgen in Puerto Rico when on site.
24 An expat (abbreviated form for expatriate) is the general word used for employees who are temporarily
or permanently residing in a country and culture other than where they come from.
With the unstable environment that the project is in, it has become increasingly more
difficult to establish a coherent team culture. The expats are feeling at risk of losing their
jobs and therefore their meaning to that situation stands in way of the importance they
should be putting on the project. Instead of having a common loyalty they tend to prefer
to expand their energy in the directions most advantageous to themselves instead of the
project team. At times like that it is difficult to keep the team members motivated. To
make things even worse, since the project has now spent almost two years on analyzing
different design alternatives, the project team has had to redo their work repeatedly. On a
regular basis team members would refer to this as feeling like it was Groundhog Day,
where the same thing happens over and over again.
With the team members drawn in from different divisions and organizations, it was really
important for the project team to learn to work together in order for the project to be
successful. During times of stress, some problems of interaction arose when the team
members were unfamiliar with their own roles in the project team. Very positive attempts
have been made to resolve those problems and improve the team spirit. For example team
logo contest, team dinners, and trips to sporting events, where everyone got the chance to
bond to further improve collaboration and sense of a common goal.
Despite good attempts to improve the team spirit, there were still some signs of
individuals who, due to the pressure of the work on their personal performance and work
stability, resisted communication among the team. Those placed obstacles in the way of
having effective interventions by all team members and blocked cooperation and
coordination. More seriously, they would criticize and blame other members of the group
when things went wrong, resent suggestions for improvement, and become defensive to
minimize culpability rather than take the initiative to maximize achievements. Those
actions were the result of the series of changes the project had been through. What the
team members had initially signed up for had changed considerably, ranging from the
scope of work to the main work location. Some of them may therefore have had the
feeling of false intentions and broken promises. They had signed up for a project that by
now should have been far into construction, but after almost two years of work has not
yet been given the green light to start construction. Frustration among team members is
inevitable but needs to be dealt with.
3.3.3 Political Lens
The project manager is the most important person the success or failure of the project.
The project manager is responsible for planning, organizing and controlling the project.
In return, the project manager holds the power to mobilize the necessary resources to
complete the project. Even though some coalitions may be formed among team members
and their different interests and goals, the decisions are negotiated at team meetings and
power base is shared by everyone on the team.
One of the main reasons for why this project is still existent despite the lack of corporate
capability to move forward with it has been the project manager's personal drive. He has
exceptional skills to exert interpersonal influence in order to lead the team. His broad
knowledge in all areas of the project, coupled with his personality enables him to interact
with his team and all the project stakeholders to keep the project alive.
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4 PART IV: Project Development Summary
As this thesis has covered, the biotechnology industry is reaching maturity in its lifecycle
and is being faced with increased responsibilities that are tightening the companies'
flexibility in terms of expenditure for new capital projects. The operating environment is
expected to remain like that and the companies have already started to adjust by
restructuring and altering their project development.
4.1 Effective time and cost management
It is challenging for the biotechnology companies to successfully manage both time and
cost. Depending on the project and the company's capabilities, there are however a few
methods that can assist with effectively managing both cost and time. Having the
organizations integrated rather than separated enables the owner to have an impact on
both shortening the project completion time and decreasing the overall project cost. That
enables faster hand-off of task between design group and construction group, and
construction activities can be organized in phases with each phase designed and
constructed in a staggered manner. The cooperation between the designer and constructer
also decreases the overall cost, as they work together to find ways to reduce construction
cost and have less need for design rework.
The choice of construction contract type depends on how much of the design is
completed before construction award. With staggered construction phases and high
confidence in the design, one preferred way for the owner would be to allocate the risk of
schedule and cost overrun to the contractor with a Guaranteed Maximum Price Contract.
4.2 Future Challenges
As the biotechnology companies adjust to the new environment of the industry, some
challenges will become more prevalent. As in other industries, proper management of the
changes will be deciding factor in determining the biotechnology companies' success in
adjusting their project development to the new environment. Effective organizational
change management is highly important for the companies to detect trends in the macro-
environment as well as in the micro-environment, and to be able to estimate what impact
the changes have on employee behavior patterns, work processes, technological
requirements, and motivation.
The biotechnology companies' main strength is in focusing on research and development
and marketing of the products. As the CMO's have become more advanced, with better
understanding of the process in the biotechnology manufacturing, it becomes an
increasingly viable option for the biotechnology companies to consider outsourcing the
product manufacturing. The companies also seek to lower cost and expand to new
markets, which can increase offshoring to counties that offer lower salaries, highly
educated workers, and supportive governments.
With increased mergers and acquisitions activities the competitors become fewer and
stronger and new organizational challenges emerge. The challenges start with the
distraction of the transaction, and continue to the post-merger organization with dealing
effectively with the increased number of customers and data, integration of systems,
corporate culture, and politics to name a few areas.
The companies in the biotechnology industry have cycled between having too little
capacity to having too much capacity. The bullwhip effect of capacity demand will
continue to be a challenge for the companies as they build their expansion strategies, due
to the increased regulatory challenges to the products in the pipeline on one hand, and
increased customer base and market demand on the other hand. As mergers and
acquisitions continue this will risk the potential of capacity shortages as majority of the
capacity will be concentrated on fewer companies.
The steep learning curve for the companies in the biotechnology industry has however
built them up, and their highly skilled and intellectual human capital will remain the
companies' biggest asset. Their passion to work in the industry for the sake of knowing
their efforts go to improving the lives of people in real need is what builds the core of the
biotechnology companies and despite being challenged with difficult times those values
will remain the source from where the companies will draw their strength.
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